Current role of perampanel in pediatric epilepsy

Ital J Pediatr. 2017 Jun 2;43(1):51. doi: 10.1186/s13052-017-0368-6.


Perampanel is among the latest AEDs approved, indicated for the treatment of partial-onset seizures with or without secondary generalization, and for primary generalized tonic-clonic seizures, in patients aged 12 years and older. This paper summarizes the clinical recommendations on the current role of perampanel in the treatment of pediatric epilepsies and future directions for research. The optimal dosage should be comprised between 4 and 12 mg/day, with 8 mg/day being the most common dosage used. The rate and severity of adverse events, including psychiatric symptoms, can be decreased by starting at low doses, and titrating slowly. Overall, perampanel presents an acceptable risk/benefit ratio, but special caution should be made to the risk of seizure aggravation and behavioral problems. The favorable cognitive profile, the ease of use of the titration scheme and the once-daily formulation offer advantage over other AEDs and make this drug particularly suitable for adolescent population. Perampanel is a welcome addition to the armamentarium of the existing AEDs, as it represents a new approach in the management of epilepsy, with a novel mechanism of action and a potential to have a considerable impact on the treatment of adolescents with epilepsy.

Keywords: AMPA; Antiepileptic drugs; Efficacy; Pediatric epilepsy; Perampanel; Tolerability.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Child
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Epilepsy / diagnosis
  • Epilepsy / drug therapy*
  • Female
  • Humans
  • Male
  • Nitriles
  • Patient Safety*
  • Prognosis
  • Pyridones / adverse effects
  • Pyridones / therapeutic use*
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome


  • Anticonvulsants
  • Nitriles
  • Pyridones
  • perampanel